raltegravir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 2352 518048-05-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • MK0518
  • isentress
  • raltegravir
  • raltegravir potassium
  • MK-0518
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus. The provirus is required to direct the production of progeny virus, so inhibiting integration prevents propagation of the viral infection.
  • Molecular weight: 444.42
  • Formula: C20H21FN6O5
  • CLOGP: 1.16
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 3
  • TPSA: 150.02
  • ALOGS: -3.66
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 9 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 25.72 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 31.80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2007 EMA
Oct. 12, 2007 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 1180.16 22.47 511 8102 107701 46569748
Foetal exposure during pregnancy 463.73 22.47 184 8429 30563 46646886
Maternal exposure during pregnancy 341.05 22.47 220 8393 102329 46575120
Abortion spontaneous 240.53 22.47 130 8483 43516 46633933
Virologic failure 180.05 22.47 47 8566 2008 46675441
Premature baby 174.56 22.47 79 8534 18033 46659416
Immune reconstitution inflammatory syndrome 167.59 22.47 56 8557 5669 46671780
Blood HIV RNULL increased 117.93 22.47 27 8586 660 46676789
Premature delivery 113.84 22.47 63 8550 22006 46655443
Drug reaction with eosinophilia and systemic symptoms 111.83 22.47 69 8544 29479 46647970
Premature labour 111.09 22.47 50 8563 11249 46666200
Lipodystrophy acquired 110.81 22.47 30 8583 1475 46675974
Pathogen resistance 104.30 22.47 40 8573 6020 46671429
Caesarean section 98.46 22.47 52 8561 16551 46660898
Live birth 96.14 22.47 44 8569 10286 46667163
Ectopic kidney 86.63 22.47 15 8598 78 46677371
Viral mutation identified 86.37 22.47 26 8587 1873 46675576
Sudden infant death syndrome 84.65 22.47 17 8596 217 46677232
Foetal growth restriction 84.00 22.47 35 8578 6532 46670917
Abortion induced 80.97 22.47 39 8574 10221 46667228
Viral load increased 80.95 22.47 23 8590 1352 46676097
Treatment noncompliance 79.74 22.47 56 8557 29675 46647774
Hepatocellular injury 66.42 22.47 50 8563 29472 46647977
Congenital heart valve disorder 65.76 22.47 12 8601 88 46677361
Neonatal respiratory arrest 63.56 22.47 11 8602 57 46677392
Gastroschisis 62.35 22.47 13 8600 202 46677247
Cloacal exstrophy 61.99 22.47 12 8601 125 46677324
Drug resistance 61.74 22.47 39 8574 17329 46660120
Congenital pulmonary valve disorder 56.98 22.47 10 8603 57 46677392
Congenital genital malformation 56.96 22.47 11 8602 113 46677336
Bladder agenesis 56.53 22.47 11 8602 118 46677331
Genitalia external ambiguous 55.40 22.47 11 8602 132 46677317
Immune reconstitution inflammatory syndrome associated tuberculosis 54.61 22.47 13 8600 378 46677071
Complication of delivery 54.44 22.47 11 8602 145 46677304
Foetal death 53.57 22.47 28 8585 8715 46668734
Meconium stain 53.31 22.47 11 8602 162 46677287
Gastrointestinal disorder congenital 52.40 22.47 10 8603 96 46677353
Meningomyelocele 51.53 22.47 13 8600 483 46676966
Premature rupture of membranes 51.32 22.47 22 8591 4401 46673048
Tethered cord syndrome 50.82 22.47 11 8602 206 46677243
Hemivertebra 50.75 22.47 10 8603 115 46677334
Caudal regression syndrome 49.91 22.47 10 8603 126 46677323
Anal atresia 49.82 22.47 12 8601 367 46677082
Maternal drugs affecting foetus 49.75 22.47 23 8590 5495 46671954
CD4 lymphocytes decreased 48.10 22.47 16 8597 1594 46675855
Generalised anxiety disorder 47.62 22.47 16 8597 1644 46675805
Pulmonary valve sclerosis 46.63 22.47 8 8605 39 46677410
Drug ineffective 45.96 22.47 35 8578 677803 45999646
Cardiac murmur 44.05 22.47 27 8586 11377 46666072
Spine malformation 43.76 22.47 10 8603 242 46677207
Hyperbilirubinaemia 43.63 22.47 26 8587 10412 46667037
Stillbirth 43.26 22.47 22 8591 6469 46670980
Gastrointestinal malformation 42.92 22.47 9 8604 144 46677305
Congenital choroid plexus cyst 42.10 22.47 10 8603 288 46677161
Renal tubular dysfunction 41.90 22.47 10 8603 294 46677155
Cholestasis of pregnancy 41.01 22.47 13 8600 1111 46676338
Exomphalos 40.87 22.47 11 8602 528 46676921
Umbilical cord abnormality 39.67 22.47 11 8602 591 46676858
Pre-eclampsia 38.96 22.47 22 8591 7972 46669477
Fall 38.76 22.47 7 8606 329090 46348359
Gestational diabetes 38.27 22.47 21 8592 7198 46670251
Low birth weight baby 37.92 22.47 19 8594 5415 46672034
Congenital anomaly 36.74 22.47 13 8600 1559 46675890
Hepatitis fulminant 36.46 22.47 16 8597 3386 46674063
Drug interaction 34.88 22.47 99 8514 202995 46474454
Pain 34.38 22.47 23 8590 476925 46200524
Product size issue 34.20 22.47 9 8604 396 46677053
Viral load decreased 34.07 22.47 6 8607 35 46677414
Large for dates baby 33.01 22.47 9 8604 454 46676995
Ventricular hypertrophy 31.61 22.47 15 8598 3799 46673650
Nephropathy toxic 29.68 22.47 18 8595 7436 46670013
Anaemia 29.67 22.47 109 8504 255670 46421779
Microcephaly 29.48 22.47 9 8604 679 46676770
Eosinophilia 29.38 22.47 26 8587 19191 46658258
Thymus hypoplasia 28.87 22.47 5 8608 26 46677423
Mental disability 27.84 22.47 6 8607 110 46677339
Oesophageal candidiasis 27.21 22.47 15 8598 5185 46672264
Genotype drug resistance test positive 27.05 22.47 8 8605 542 46676907
Mitochondrial cytopathy 26.80 22.47 7 8606 299 46677150
Diastasis recti abdominis 26.49 22.47 5 8608 45 46677404
Rash maculo-papular 26.34 22.47 29 8584 27845 46649604
Small for dates baby 26.21 22.47 13 8600 3624 46673825
Antiviral drug level below therapeutic 25.92 22.47 5 8608 51 46677398
Cholestasis 25.45 22.47 28 8585 26865 46650584
Chronic papillomatous dermatitis 25.18 22.47 5 8608 60 46677389
Congenital ectopic bladder 24.81 22.47 5 8608 65 46677384
Amniotic cavity infection 24.73 22.47 9 8604 1169 46676280
Anencephaly 24.71 22.47 6 8607 190 46677259
Neural tube defect 24.59 22.47 6 8607 194 46677255
Acute stress disorder 24.10 22.47 6 8607 211 46677238
Fatigue 23.74 22.47 48 8565 608649 46068800
Hepatotoxicity 23.60 22.47 26 8587 24983 46652466
Pregnancy 23.53 22.47 27 8586 27110 46650339
Dermatitis exfoliative 23.27 22.47 14 8599 5702 46671747
Pulmonary tuberculosis 22.99 22.47 13 8600 4718 46672731
Bronchopulmonary dysplasia 22.69 22.47 6 8607 269 46677180
Hemiataxia 22.61 22.47 4 8609 24 46677425
Aqueductal stenosis 22.61 22.47 4 8609 24 46677425
Patent ductus arteriosus 22.61 22.47 12 8601 3850 46673599

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 463.91 14.11 566 16437 199002 29736473
Depression 415.13 14.11 370 16633 90067 29845408
Immune reconstitution inflammatory syndrome 361.06 14.11 150 16853 8951 29926524
Lipodystrophy acquired 344.08 14.11 113 16890 3447 29932028
Virologic failure 334.72 14.11 108 16895 3111 29932364
Foetal exposure during pregnancy 282.41 14.11 204 16799 36667 29898808
Pathogen resistance 259.22 14.11 116 16887 8294 29927181
Mitochondrial toxicity 243.72 14.11 80 16923 2434 29933041
Progressive external ophthalmoplegia 224.15 14.11 64 16939 1202 29934273
Eyelid ptosis 197.25 14.11 83 16920 5105 29930370
Viral mutation identified 181.99 14.11 65 16938 2561 29932914
Blood HIV RNULL increased 165.70 14.11 52 16951 1364 29934111
Drug resistance 144.02 14.11 107 16896 20026 29915449
Viral load increased 126.61 14.11 51 16952 2803 29932672
Renal tubular disorder 102.07 14.11 52 16951 4954 29930521
Diplopia 100.27 14.11 74 16929 13698 29921777
Gene mutation 87.17 14.11 28 16975 793 29934682
Volvulus 78.86 14.11 29 16974 1242 29934233
Drug reaction with eosinophilia and systemic symptoms 77.40 14.11 88 16915 28400 29907075
Brachydactyly 75.80 14.11 18 16985 156 29935319
Osteoporotic fracture 69.19 14.11 25 16978 1018 29934457
CD4 lymphocytes decreased 68.40 14.11 30 16973 2040 29933435
HIV infection 64.43 14.11 27 16976 1641 29933834
Depression suicidal 60.75 14.11 24 16979 1252 29934223
Loss of personal independence in daily activities 59.30 14.11 67 16936 21468 29914007
Extraocular muscle paresis 58.35 14.11 18 16985 445 29935030
Ophthalmoplegia 56.79 14.11 23 16980 1281 29934194
Psychiatric decompensation 56.60 14.11 23 16980 1292 29934183
Hepatitis C 56.27 14.11 52 16951 13153 29922322
HIV-associated neurocognitive disorder 54.84 14.11 16 16987 325 29935150
Treatment failure 53.37 14.11 81 16922 34598 29900877
CSF HIV escape syndrome 50.03 14.11 12 16991 109 29935366
Cytomegalovirus chorioretinitis 49.87 14.11 28 16975 3240 29932235
Oesophageal candidiasis 48.31 14.11 30 16973 4180 29931295
Genital herpes 47.42 14.11 16 16987 530 29934945
Tearfulness 45.93 14.11 21 16982 1575 29933900
Oesophageal atresia 45.59 14.11 15 16988 459 29935016
Hemivertebra 45.37 14.11 11 16992 105 29935370
Gastrointestinal tube insertion 43.73 14.11 19 16984 1262 29934213
Osteoporosis 43.52 14.11 41 16962 10622 29924853
Laryngomalacia 40.40 14.11 12 16991 260 29935215
Drug level decreased 39.58 14.11 30 16973 5775 29929700
Paranoia 39.35 14.11 38 16965 10150 29925325
Genital herpes simplex 38.57 14.11 10 16993 128 29935347
Renal impairment 37.51 14.11 119 16884 84065 29851410
Low birth weight baby 36.21 14.11 29 16974 6047 29929428
Anogenital dysplasia 35.72 14.11 10 16993 174 29935301
Completed suicide 34.94 14.11 7 16996 99485 29835990
Anal cancer 34.72 14.11 12 16991 428 29935047
Genotype drug resistance test positive 33.83 14.11 17 16986 1572 29933903
Superior mesenteric artery syndrome 33.42 14.11 8 16995 72 29935403
Premature baby 33.07 14.11 44 16959 16647 29918828
Congenital mitral valve incompetence 32.75 14.11 8 16995 79 29935396
Blood creatine phosphokinase increased 31.59 14.11 74 16929 43774 29891701
Atrial fibrillation 31.54 14.11 11 16992 108113 29827362
Hepatic cirrhosis 31.43 14.11 42 16961 15957 29919518
Dyslipidaemia 31.32 14.11 26 16977 5701 29929774
HIV lipodystrophy 30.30 14.11 6 16997 19 29935456
Suicidal ideation 29.42 14.11 64 16939 36050 29899425
Drug abuse 28.34 14.11 6 16997 82066 29853409
Spine malformation 28.17 14.11 8 16995 147 29935328
Congenital skin dimples 27.97 14.11 8 16995 151 29935324
HIV associated nephropathy 27.78 14.11 9 16994 262 29935213
Pneumonia 27.26 14.11 98 16905 334208 29601267
Dyspnoea 26.98 14.11 98 16905 333197 29602278
Fanconi syndrome acquired 26.73 14.11 16 16987 2087 29933388
Adverse event 26.72 14.11 38 16965 15303 29920172
Intestinal malrotation 26.65 14.11 6 16997 40 29935435
Hypotension 26.30 14.11 46 16957 200519 29734956
Nephrolithiasis 26.21 14.11 49 16954 24761 29910714
Drug level increased 25.61 14.11 41 16962 18313 29917162
Hepatic enzyme decreased 24.77 14.11 6 16997 57 29935418
Enanthema 24.28 14.11 9 16994 394 29935081
Nephropathy toxic 24.14 14.11 30 16973 10609 29924866
Confusional state 23.65 14.11 25 16978 134809 29800666
Cholestasis 23.57 14.11 47 16956 24903 29910572
Hyperlipidaemia 23.56 14.11 34 16969 13873 29921602
Disease progression 23.51 14.11 8 16995 79866 29855609
Haemophilic arthropathy 23.38 14.11 7 16996 156 29935319
Congenital vesicoureteric reflux 23.11 14.11 5 16998 27 29935448
Mycobacterium avium complex infection 23.01 14.11 16 16987 2695 29932780
Oesophageal carcinoma 22.84 14.11 17 16986 3184 29932291
Dysphagia 22.41 14.11 77 16926 56621 29878854
Depressive symptom 22.17 14.11 13 16990 1632 29933843
Acquired immunodeficiency syndrome 22.16 14.11 9 16994 505 29934970
Lymphoma 22.11 14.11 28 16975 10093 29925382
Hypertriglyceridaemia 21.95 14.11 25 16978 8073 29927402
Fall 21.82 14.11 44 16959 181828 29753647
Back pain 21.62 14.11 16 16987 102580 29832895
Hyperbilirubinaemia 21.16 14.11 36 16967 16906 29918569
Osteonecrosis 21.10 14.11 35 16968 16100 29919375
Treatment noncompliance 20.84 14.11 45 16958 25208 29910267
Acquired gene mutation 20.63 14.11 11 16992 1150 29934325
Jaundice 20.38 14.11 52 16951 32434 29903041
Hemiparaesthesia 20.32 14.11 5 16998 51 29935424
Cardiac arrest 20.19 14.11 14 16989 92836 29842639
VACTERL syndrome 20.12 14.11 4 16999 13 29935462
Antiviral drug level above therapeutic 19.98 14.11 5 16998 55 29935420
Heart transplant rejection 19.84 14.11 11 16992 1242 29934233
Myopathy 19.59 14.11 27 16976 10559 29924916
Congenital ureteric anomaly 19.47 14.11 4 16999 16 29935459
Hyperphagia 19.19 14.11 11 16992 1324 29934151
Chronic hepatitis C 19.00 14.11 8 16995 492 29934983
Cachexia 18.92 14.11 21 16982 6590 29928885
Congenital renal disorder 18.68 14.11 5 16998 73 29935402
Acute hepatitis C 18.64 14.11 6 16997 171 29935304
Lipohypertrophy 18.62 14.11 7 16996 319 29935156
Pulmonary tuberculosis 18.54 14.11 18 16985 4839 29930636
Respiratory failure 18.39 14.11 18 16985 100624 29834851
Cerebral ventricle dilatation 18.31 14.11 9 16994 793 29934682
Infection 18.02 14.11 11 16992 78063 29857412
Choroiditis 17.97 14.11 9 16994 826 29934649
Cardiomyopathy acute 17.72 14.11 4 16999 27 29935448
Lymphocytic infiltration 17.70 14.11 8 16995 584 29934891
Drug-induced liver injury 17.66 14.11 38 16965 21236 29914239
Intensive care unit acquired weakness 17.60 14.11 9 16994 863 29934612
Hepatitis cholestatic 17.55 14.11 22 16981 7850 29927625
Syphilis 17.52 14.11 7 16996 376 29935099
Tracheal fistula repair 17.35 14.11 3 17000 3 29935472
Rash maculo-papular 17.33 14.11 42 16961 25376 29910099
Meningitis cryptococcal 17.31 14.11 12 16991 2012 29933463
Retinal toxicity 17.24 14.11 7 16996 392 29935083
Vertigo 17.17 14.11 39 16964 22596 29912879
Toxicity to various agents 17.15 14.11 48 16955 177135 29758340
Pancreatitis acute 17.03 14.11 42 16961 25653 29909822
Abnormal dreams 17.01 14.11 22 16981 8093 29927382
Hepatic failure 16.88 14.11 50 16953 33993 29901482
Seborrhoeic dermatitis 16.86 14.11 10 16993 1283 29934192
Glycosuria 16.73 14.11 10 16993 1301 29934174
Congenital hydronephrosis 16.67 14.11 8 16995 669 29934806
Myelocytosis 16.61 14.11 4 16999 37 29935438
Constipation 16.57 14.11 24 16979 112882 29822593
Renal failure 16.25 14.11 127 16876 128839 29806636
Liver disorder 16.04 14.11 45 16958 29677 29905798
Erosive duodenitis 16.04 14.11 10 16993 1403 29934072
Nephrocalcinosis 15.98 14.11 7 16996 474 29935001
Insomnia 15.94 14.11 99 16904 93237 29842238
Lymphogranuloma venereum 15.82 14.11 3 17000 7 29935468
Fat tissue decreased 15.74 14.11 4 16999 47 29935428
Hepatotoxicity 15.74 14.11 33 16970 18112 29917363
Kidney enlargement 15.60 14.11 8 16995 772 29934703
Malignant neoplasm progression 15.58 14.11 11 16992 72276 29863199
Birth trauma 15.53 14.11 3 17000 8 29935467
Atypical mycobacterial infection 15.43 14.11 8 16995 790 29934685
Tracheal deviation 15.27 14.11 3 17000 9 29935466
Psychomotor skills impaired 15.22 14.11 11 16992 1968 29933507
Hepatitis B 15.21 14.11 18 16985 6054 29929421
Alopecia areata 15.20 14.11 5 16998 153 29935322
Subacute combined cord degeneration 15.20 14.11 5 16998 153 29935322
Hepatorenal syndrome 14.99 14.11 12 16991 2499 29932976
Induration 14.90 14.11 8 16995 848 29934627
Cardio-respiratory arrest 14.80 14.11 7 16996 57299 29878176
Proteinuria 14.75 14.11 30 16973 16115 29919360
Pneumocystis jirovecii pneumonia 14.69 14.11 31 16972 17089 29918386
Cardiac failure congestive 14.40 14.11 16 16987 84391 29851084
Congenital syphilis 14.23 14.11 3 17000 14 29935461
Intervertebral discitis 14.20 14.11 10 16993 1719 29933756
Adrenal suppression 14.15 14.11 7 16996 626 29934849

Pharmacologic Action:

SourceCodeDescription
ATC J05AJ01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Integrase inhibitors
ATC J05AR16 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000000127 HIV Integrase Inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019428 HIV Integrase Inhibitors
MeSH PA D019429 Integrase Inhibitors
FDA EPC N0000175887 Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
CHEBI has role CHEBI:36044 anti-virus drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Disorder of muscle contraindication 129565002 DOID:423
Rhabdomyolysis contraindication 240131006
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.19 acidic
pKa2 10.89 acidic
pKa3 12.18 acidic
pKa4 2.3 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 400MG BASE ISENTRESS MERCK SHARP DOHME N022145 Oct. 12, 2007 RX TABLET ORAL May 22, 2021 PEDIATRIC EXCLUSIVITY
EQ 600MG BASE ISENTRESS HD MERCK SHARP DOHME N022145 May 26, 2017 RX TABLET ORAL May 22, 2021 PEDIATRIC EXCLUSIVITY
EQ 100MG BASE ISENTRESS MERCK SHARP DOHME N203045 Dec. 21, 2011 RX TABLET, CHEWABLE ORAL May 22, 2021 PEDIATRIC EXCLUSIVITY
EQ 25MG BASE ISENTRESS MERCK SHARP DOHME N203045 Dec. 21, 2011 RX TABLET, CHEWABLE ORAL May 22, 2021 PEDIATRIC EXCLUSIVITY
EQ 100MG BASE/PACKET ISENTRESS MERCK SHARP DOHME N205786 Dec. 20, 2013 RX POWDER ORAL May 22, 2021 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
C-C chemokine receptor type 1 GPCR Ki 8.30 CHEMBL
Integrase Enzyme INHIBITOR IC50 8 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein INHIBITOR IC50 7.52 WOMBAT-PK
Integrase Enzyme IC50 5.74 CHEMBL

External reference:

IDSource
D06676 KEGG_DRUG
871038-72-1 SECONDARY_CAS_RN
4026736 VANDF
C1966407 UMLSCUI
CHEBI:82960 CHEBI
RLT PDB_CHEM_ID
CHEMBL254316 ChEMBL_ID
CHEMBL518520 ChEMBL_ID
D000068898 MESH_DESCRIPTOR_UI
DB06817 DRUGBANK_ID
11571 IUPHAR_LIGAND_ID
8842 INN_ID
22VKV8053U UNII
23668479 PUBCHEM_CID
1235585 RXNORM
121359 MMSL
24597 MMSL
31069 MMSL
d07048 MMSL
012364 NDDF
012365 NDDF
429368003 SNOMEDCT_US
429707008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 0006-0227 TABLET, FILM COATED 400 mg ORAL NDA 31 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 0006-0473 TABLET, CHEWABLE 25 mg ORAL NDA 31 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 0006-0477 TABLET, CHEWABLE 100 mg ORAL NDA 31 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3080 TABLET, FILM COATED 600 mg ORAL NDA 31 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3603 GRANULE, FOR SUSPENSION 100 mg ORAL NDA 31 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 50090-1085 TABLET, FILM COATED 400 mg ORAL NDA 30 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 53808-0650 TABLET, FILM COATED 400 mg ORAL NDA 28 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 54868-0117 TABLET, FILM COATED 400 mg ORAL NDA 30 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 61919-706 TABLET, FILM COATED 400 mg ORAL NDA 15 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 61919-706 TABLET, FILM COATED 400 mg ORAL NDA 15 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 66336-214 TABLET, FILM COATED 400 mg ORAL NDA 30 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 67296-1235 TABLET, FILM COATED 400 mg ORAL NDA 18 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 68071-2113 TABLET, FILM COATED 400 mg ORAL NDA 29 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 70518-1621 TABLET, FILM COATED 400 mg ORAL NDA 30 sections
ISENTRESS HUMAN PRESCRIPTION DRUG LABEL 1 76519-1130 TABLET, FILM COATED 400 mg ORAL NDA 17 sections